CAR-T Illustration. Courtesy New Scientist
A recent head-to-head study assessed the comparative effectiveness of different B-cell depletion strategies in patients with autoimmune diseases, specifically comparing protein-based therapies like obinutuzumab (OBI), blinatumomab (BLI), and rituximab (RTX) with cell-based CD19 chimeric antigen receptor (CAR) T-cell therapy. Researchers analyzed lymph node biopsies to assess the extent of B-cell depletion and changes in follicular architecture. They documented that CAR-T was most effective in depleting B cells and disrupting follicular architecture, and concluded that these data indicate potential superiority of CAR-T cell therapies.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.drugdevelop.com/subscribe
Popular Podcasts
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.
24/7 News: The Latest
The latest news in 4 minutes updated every hour, every day.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.